Next Generation Vaccine Development and Commercial Production to Defeat Future Pandemic Viruses

Prestige Biopharma has been preparing for a business expansion into the development and production of vaccine-based therapeutics since the start of the ongoing COVID-19 outbreak as a response to the current, and potential future, viral pandemics. Since when COVID-19 was in full swing, the company has prepared its facilities, manpower, and project experience for the vaccine business. Prestige has been discussing partnership with many global biopharmaceuticals including the Australian vaccine developer Vaxine and the US biopharma firm Benevira.

At Prestige Group, Prestige Biopharma will work together with its manufacturing arm, Prestige Biologics, for the success of contract manufacturing business. Prestige’s Vaccine Center in Osong, Korea is a world-class, state-of-the-art facility with a total production capacity of 88,000 liters.